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In the history of surgical oncology, survival benefit of
extended lymphadenectomy has been a focus of debates in
gastrointestinal carcinomas.1 The fear for the invisible
metastasis prompted surgeons to perform more aggressive
resections with lymphadenectomy to control the disease
locally. However, the clinical significance of extended
lymphadenectomy has been the subject of controversy over
the past 10 years.2–4 On the other hand, the histopatholo-
gical status of regional lymph nodes is one of the most
reliable predictors of recurrence and overall survival for
most gastrointestinal cancer, and it is often used to justify
stratification of patients for adjuvant therapy.
Gastric cancer is the second leading cause of cancer
death worldwide; it is particularly common in Asian
countries, including Japan. To date, several classifications
of lymph node metastasis is considered for patients with
gastric cancer. Classification was based on the anatomical
location of nodal involvement has been established in the
Japanese Gastric Cancer Association. The total number of
involved lymph nodes is also considered as the N status
defined by the American Joint Committee on Cancer
(AJCC) and the International Union Against Cancer
(UICC). In the 5th and 6th editions of the AJCC/UICC
tumor, node, metastasis system (TNM) classification, the N
status for gastric cancer was defined as follows: N0, no
regional lymph node metastasis; N1, metastasis in 1–6
regional lymph nodes; N2, metastasis in 7–15 regional
lymph nodes; and N3, metastasis in C16 regional lymph
nodes. On the other hand, in the most recent UICC TNM
staging system (7th edition) redefined N status is catego-
rized into N0, no regional lymph node metastasis; N1,
metastasis in 1–3 regional lymph nodes; N2, metastasis in
4–6 regional lymph nodes; N3a, metastasis in 7–15 regio-
nal lymph nodes; and N3b, metastasis in C 16 regional
lymph nodes. A recent article by Deng et al. indicated that
the 7th edition UICC N status would provide more reliable
prognostic information than the 5th/6th edition UICC N
status by analysis of the 456 patients with gastric cancer
after curative surgery.5 However, N status by the AJCC/
UICC TNM staging is restricted by regional lymphade-
nectomy, in which at least 15 lymph nodes should be
examined, because stage migration that results from the
number of dissected lymph nodes is frequently recognized
as one of the major concerns in the AJCC/UICC staging
system for gastric cancer.
Recent investigations have emphasized the clinical
utility of a new lymph node staging (N ratio) that is based
on the number of positive lymph nodes divided by the
number of examined lymph nodes.6,7 Inoue et al. showed
that the N ratio was the most statistically significant
prognostic factor, whereas the N status by the AJCC/UICC
staging system was not found to be significant by multi-
variate analysis of the 1019 patients with gastric cancer
who underwent R0 resection.6 Recently Bando et al. also
reported that the N ratio was well correlated with prognosis
for 777 patients with advanced gastric cancer, as an inde-
pendent prognostic factor in a multivariate analysis.7
Moreover, the N ratio was a statistically significant prog-
nostic factor in N1, N2, and N3 patients defined by the
Japanese classification of disease.
The current article by Maduekwe et al. reports on the N
ratio in 257 patients undergoing D1 lymphadenectomy for
gastric cancer.8 The authors note that there was no statis-
tically significant difference in overall survival between
patients with \15 and C15 nodes examined when they
stratified N ratio intervals. They concluded that the N ratio
is more reliable as a prognostic indicator minimizing stage
migration compared to the N status by the 6th edition
AJCC/UICC TNM staging system, even in patients with
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D1 lymphadenectomy in which \15 lymph nodes were
excised. The article may represent a valuable signpost for
the future direction of the lymph node staging system. If
the N ratio is really feasible even to the patients with D1
lymphadenectomy, discrepancy in prognosis of gastric
cancer patients between Japan and Western countries,
which is partly believed to be the result of stage migration,
could be avoided. However, its results should be inter-
preted in context with caution. First, the authors set up a
unique category, Nr0, which was designated only for
patients with no lymph node metastasis among C15 lymph
nodes examined, but not for patients with \15 nodes. If
Nr0 disease was indicated even in patients with\15 nodes
examined, the survival of patients with Nr0 and Nr1 dis-
ease who had \15 nodes examined might be much worse
than that Nr0 and Nr1 disease in patients with C15 nodes,
respectively. Is their stratification universally applicable to
every institution in the world?
Second, unfortunately, the current article from Mad-
uekwe et al. was based on the retrospective review of a
smaller number of patients compared to previous
reports.6–9 Sun et al. recently showed the similar results
that the N ratio has advantages in minimizing stage
migration for patients with insufficient number of lymph
nodes excised or patients with D1 lymphadenectomy from
their series of 2159 patients with gastric cancer.9 Because
the study of Maduekwe et al. was also mentioned in the
article, the new N ratio stratification should be validated by
a large prospective study in the future.8
Third, are there any therapeutic effects of extended
lymphadenectomy or resection of more lymph nodes? In
Japan and other Asian countries, extensive (D2) lym-
phadenectomy has been performed as standard procedures
for mid to advanced gastric cancer because it is believed
that extensive lymphadenectomy is effective in controlling
the disease locally. To date, two large European random-
ized trial that compared D1 with D2 lymphadenectomy, the
Dutch trial and British Medical Research Council Trial,
both failed to show a survival benefit in the favor of D2
dissection.2,3 However, these trials have been criticized for
poor quality of surgical techniques and extremely high
mortality rate (10 and 13%) after D2 lymphadenectomy. If
D2 lymphadenectomy is performed with low morbidity and
mortality, it is likely to have a marked benefit compared
to D1 lymphadenectomy.2,3,10 A recent Taiwanese trial
comparing D1 with D2?a proved a modest survival benefit
for D2?a dissection over D1, with statistical significance,
although the trial had several issues to resolve.4
Clinical benefit of D1/D2 lymphadenectomy for gastric
cancer in terms of accurate staging and locoregional con-
trol should be validated by carefully designed multicenter
prospective randomized trials in Western and/or Asian
countries. Further exploration may clarify where it should
be positioned in surgical oncology for gastric cancer.
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